A Phase II clinical study using metformin, pemetrexed, and carboplatin for the treatment of STK11-mutated NSCLC did not demonstrate the expected efficacy (CTRI/2019/02/0017815) [31]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.